Acute Pyelonephritis Diagnosis: A Comprehensive Guide for Auto Repair Professionals and Healthcare Insights

Introduction

Acute pyelonephritis, commonly known as a kidney infection, is characterized by bacterial-induced inflammation of the renal tissues. It frequently arises as a complication of an ascending urinary tract infection (UTI), where bacteria travel upwards from the bladder to the kidneys. However, the infection can also spread through the bloodstream, a process known as hematogenous spread. Certain patient groups, including children, individuals with kidney transplants, and pregnant women, require particular consideration due to their unique vulnerabilities. The typical presentation of acute pyelonephritis encompasses symptoms like fever, pain in the flank, nausea, vomiting, and urinary symptoms such as burning during urination, increased frequency, and urgency.

A critical aspect of clinical assessment is differentiating acute pyelonephritis, which is primarily managed with antibiotic therapy, from pyonephrosis, also referred to as obstructive pyelonephritis. Pyonephrosis presents with similar symptoms but necessitates immediate surgical drainage to relieve obstruction in an infected renal pelvis. The microorganisms involved in pyelonephritis can be diverse, and antibiotic resistance is a growing concern. Medical imaging plays a vital role in diagnosis and monitoring treatment response. This article provides a detailed overview of the clinical presentation, Pyelo Diagnosis, and management strategies for acute pyelonephritis, emphasizing the collaborative roles of various healthcare professionals in patient care.

Etiology of Acute Pyelonephritis

Bacteria can reach the kidneys through two main routes: hematogenous spread and ascending infection from the lower urinary tract. Hematogenous spread, while less frequent, typically occurs in individuals with weakened immune systems, underlying health issues, or urinary tract blockages. In these cases, bacteria enter the bloodstream and subsequently reach the kidneys.

Ascending infection is the more common pathway for acute pyelonephritis. This process begins with the contamination of the periurethral area by pathogens originating from the rectum. These bacteria initially adhere to the epithelial cells lining the urethra and then ascend to the bladder. From the bladder, bacteria must overcome the body’s natural defenses and multiply sufficiently to progress up the ureters and reach the kidneys. Urinary tract infections are more prevalent in females due to anatomical factors such as a shorter urethra, hormonal influences, and the urethra’s proximity to the anus.

Any obstruction in the urinary outflow can impede complete bladder emptying, leading to urinary stasis. This stagnation allows bacteria to multiply without being effectively flushed out by urination. Urinary tract obstruction, often caused by kidney stones, can also lead to obstructive pyelonephritis or pyonephrosis, a severe and potentially life-threatening form of acute pyelonephritis.

Vesicoureteral reflux (VUR), a congenital condition where urine abnormally flows backward from the bladder into the kidneys during urination, is another less common cause. It’s estimated that up to 40% of children diagnosed with a UTI also have vesicoureteral reflux. Approximately 10% of children with VUR may develop renal scarring, potentially leading to long-term kidney dysfunction.

Kidney transplant recipients are at an elevated risk of developing pyelonephritis due to a combination of factors, including immunosuppression and the altered anatomy of the transplanted kidney, particularly in the initial six months post-transplant. Studies have indicated that even a single episode of pyelonephritis in transplant recipients can significantly increase the risk of transplant failure and mortality.

The Microbiology of Pyelonephritis

Escherichia coli (E. coli) is overwhelmingly the most frequent cause of acute pyelonephritis and the majority of UTIs. Klebsiella pneumoniae is the second most common bacterial agent, followed by Proteus, Pseudomonas, Enterococci, Staphylococci, and other enterobacteria.

Candida spp, a type of fungus, can also be a causative agent, particularly in patients with diabetes, elderly individuals, those who have received extensive antibiotic treatments, hospitalized patients (especially in intensive care units), and individuals with indwelling catheters. Candida spp can form fungal masses and radiolucent filling defects in the urinary tract, further complicating treatment.

The increasing occurrence of bacteria producing extended-spectrum beta-lactamases (ESBL) and resistance to fluoroquinolone antibiotics significantly complicates antibiotic selection for these serious infections. Antibiotic resistance is a growing global health concern. Over 90% of bacteria causing UTIs exhibit resistance to at least one antibiotic, and nearly 80% are resistant to two or more antibiotics.

Patient risk factors for antibiotic resistance include recent broad-spectrum antibiotic use (especially quinolones and beta-lactams), urinary tract obstruction, frequent healthcare encounters, recurrent UTIs, hospital admissions, indwelling catheters, advanced age, and inappropriate antibiotic use (e.g., incorrect dosage, inadequate or prolonged treatment duration, or improper antibiotic choice).

Other contributing factors to antibiotic resistance include the overall overuse of antibiotics in healthcare and agriculture, the availability of antibiotics without prescriptions in many regions, global travel and migration patterns, failure to adhere to best practice guidelines for antibiotic use, and inadequate restrictions on the use of last-resort antibiotics.

Generally, an antibiotic is considered clinically effective if community-level bacterial resistance is 10% or less. Antibiotics with limited tissue penetration or urinary excretion, such as nitrofurantoin, are typically not recommended for treating pyelonephritis.

In developing countries, specific challenges contribute to the complexity of pyelonephritis management, including delays in seeking appropriate medical care due to poverty, reliance on alternative therapies from traditional healers, inadequate healthcare infrastructure and sanitation, limited patient education, governmental regulatory issues such as not participating in the WHO’s Global Antibiotic Resistance Partnership (GARP), and lack of resources to detect counterfeit drugs or verify medication quality.

Epidemiology of Acute Pyelonephritis

In the United States, acute pyelonephritis occurs at an estimated annual rate of 15 to 17 cases per 10,000 females and 3 to 4 cases per 10,000 males. This translates to approximately 250,000 cases reported annually in the US. A large-scale study in Sweden involving over 750,000 patients found that uncomplicated UTI/cystitis progressed to pyelonephritis in 0.47% of cases when treated with antibiotics. This risk increased to 1.43% if antibiotic treatment was not initiated within five days of cystitis diagnosis.

Young, sexually active women are most frequently affected by acute pyelonephritis due to their higher incidence of UTIs. However, men tend to have a higher mortality rate from pyelonephritis. This disparity may be attributed to men being more likely to have underlying conditions such as diabetes, kidney stones, or pre-existing kidney disease. Individuals at the extremes of age, including older adults and infants, are also at increased risk. Acute pyelonephritis does not show any racial predisposition.

Pregnant women are considered a high-risk group due to physiological changes during pregnancy that increase susceptibility to UTIs. Acute pyelonephritis in pregnancy can lead to maternal complications and, in some studies, preterm delivery and low birth weight. Asymptomatic bacteriuria, the presence of bacteria in the urine without symptoms, occurs in 2% to 7% of pregnant women. While clinical guidelines in North America and Europe have historically recommended screening for and treating asymptomatic bacteriuria in pregnant women to prevent pyelonephritis, these recommendations were based on older studies now considered to be of low quality. More recent data suggests no significant difference in pyelonephritis rates with treatment of asymptomatic bacteriuria, and the overall incidence of pyelonephritis was low in both treated and untreated groups. Therefore, current evidence suggests that routine treatment of asymptomatic bacteriuria in pregnant women may not be necessary, especially considering potential adverse effects of antibiotics. Further high-quality, randomized controlled trials are needed to definitively address this issue.

Pathophysiology of Acute Pyelonephritis

E. coli‘s ability to cause acute pyelonephritis is largely attributed to its unique mechanisms for adhering to and colonizing the urinary tract and kidneys. E. coli possesses adhesive appendages called P-fimbriae, which interact with specific receptors on the surface of uroepithelial cells, facilitating bacterial attachment. Animal studies have demonstrated that neutrophils are crucial for controlling bacterial ascent in the urinary tract, while macrophages play a significant role in the inflammatory response and subsequent renal scarring.

When kidneys become infected with E. coli, they initiate an acute inflammatory response, releasing chemokines and other inflammatory mediators. Beyond the localized inflammation, this process can ultimately lead to scarring of the renal parenchyma, the functional tissue of the kidney. Animal models have shown collagen deposition in areas surrounding renal abscesses, suggesting that connective tissue replaces functional renal tissue as a way to contain bacterial spread. Renal scarring likely results from a combination of factors, including disruption of renal cell barriers, localized inflammation, cytokine release, blood clotting, and tissue hypoxia. Inflammatory cytokines, bacterial toxins, and other reactive processes contribute to the widespread renal involvement characteristic of pyelonephritis and can progress to systemic complications like sepsis and septic shock.

Histopathology of Acute Pyelonephritis

Mucosal injury is a prominent feature of acute pyelonephritis. Histopathological examination reveals submucosal collections of inflammatory cells and engorged peritubular capillaries. The extent of mucosal injury can range from superficial erosions to more severe ulceration. Submucosal collagen deposition and engorged peritubular capillaries are also evident in the acute phase. Renal tissues show marked infiltration by neutrophils, macrophages, and plasma cells. Plugs composed of inflammatory cells and debris may form within the renal tubules, sometimes extending into the surrounding interstitium. This process can lead to focal degeneration or destruction of the renal tubules, manifesting as localized areas of necrosis and microabscess formation within the renal parenchyma.

History and Physical Examination in Pyelonephritis Diagnosis

Acute pyelonephritis typically presents with a classic triad of symptoms: fever, flank pain, and nausea or vomiting. However, it’s important to note that not all of these symptoms need to be present for a pyelo diagnosis. In patients who do not experience nausea or vomiting, anorexia (loss of appetite) is a common symptom.

Symptoms usually develop rapidly, over several hours or within a day. Cystitis symptoms, such as dysuria (painful urination) and hematuria (blood in urine), are more commonly reported by women.

In children, the typical symptoms of acute pyelonephritis may be absent or less specific. In neonates and children under two years old, common symptoms include failure to thrive, fever, and feeding difficulties. Elderly patients may present with atypical symptoms such as sudden onset of dementia or altered mental status, fever, loss of appetite, kidney dysfunction, and involvement of other organ systems.

When fever is present in pyelonephritis, it can be high, often exceeding 103 °F (39.4 °C). Despite the potential for high fever, patients with acute pyelonephritis generally do not appear severely ill or toxic and may seem reasonably well in their overall appearance.

Vital signs are typically within normal ranges, but a systolic blood pressure below 90 mm Hg may indicate a more severe disease process and potential sepsis.

Physical examination findings in pyelonephritis can vary.

• Costovertebral angle tenderness, elicited by tapping or pressing over the angle formed by the rib cage and spine, is commonly unilateral, corresponding to the affected kidney. However, bilateral costovertebral angle tenderness can occur in some cases.

• Suprapubic tenderness, pain upon palpation of the lower abdomen above the pubic bone, may range from minimal to moderate.

• Rebound tenderness, guarding, and rigidity, signs of peritoneal irritation, are generally absent. Abdominal tenderness, other than in the suprapubic area, is typically not present.

• Bowel sounds are usually present and active. The skin typically appears normal, except in cases where Herpes zoster (shingles) might be a differential diagnosis.

• Clinical presentations of pyelonephritis in men, older adults, and young children can be more variable and may deviate from the classic symptom triad.

Evaluation and Pyelo Diagnosis

A thorough medical history and physical examination are fundamental in the evaluation of suspected acute pyelonephritis. Laboratory and imaging studies are valuable adjuncts to confirm the pyelo diagnosis and assess disease severity.

A urine specimen should always be obtained for urinalysis and urine culture in patients suspected of pyelonephritis. In situations where a patient is unable to void adequately, even with hydration, or in specific patient populations such as morbidly obese females, patients too ill to reliably collect a clean-catch specimen, and young children, urethral catheterization may be necessary. Suprapubic aspiration is a reasonable alternative for urine collection in young children. Obtaining a urine specimen before starting antibiotics significantly improves the yield of urine culture. Despite this, urine cultures can be negative in up to 30% of pyelonephritis cases, potentially due to prior outpatient antibiotic use. Blood cultures are often obtained but rarely alter the treatment course, as urine culture results are typically more informative.

Urinalysis in acute pyelonephritis commonly reveals pyuria, the presence of white blood cells in the urine.

• Proteinuria, bacteriuria (bacteria in urine), and microscopic hematuria (red blood cells in urine) may also be present. If hematuria is noted, other conditions such as kidney stones should be considered in the differential pyelo diagnosis. Gross hematuria, visible blood in the urine, is observed in up to 40% of young women with acute pyelonephritis, but is less common in men with this infection. Microscopic examination of unspun urine under oil immersion revealing a single bacterium suggests a bacterial concentration of at least 100,000 colony-forming units (cfu)/mL, supporting the pyelo diagnosis.

Blood tests, such as a complete blood cell count (CBC), are performed to assess for leukocytosis (elevated white blood cell count) and other laboratory indicators of sepsis. A complete metabolic panel can evaluate kidney function by measuring creatinine and blood urea nitrogen (BUN) levels. Currently, there are no serum biomarkers specifically diagnostic for pyelonephritis. However, urinary neutrophil gelatinase-associated lipocalin (uNGAL) has emerged as a potentially useful and sensitive marker for acute pyelonephritis, particularly in children and possibly in adults. A threshold value of 29.4 ng/mL for uNGAL has been suggested, demonstrating high sensitivity and specificity in pediatric acute pyelonephritis.

In addition to urine cultures, laboratory evaluation for suspected urinary sepsis should be conducted when clinically indicated. This may include measuring C-reactive protein (CRP), lactic acid, procalcitonin, and the neutrophil-to-lymphocyte ratio (NLR), with an NLR greater than 5 suggesting sepsis.

Imaging studies are generally not required for pyelo diagnosis in uncomplicated acute pyelonephritis. However, imaging should be considered for patients at high risk of complications or when there is diagnostic uncertainty.

High-risk patients who should be considered for imaging include individuals with diabetes (especially poorly controlled diabetes), recurrent pyelonephritis, known anatomical or surgically corrected urinary tract abnormalities, hospital-acquired infections, sepsis, kidney stones (urolithiasis), kidney transplant recipients, immunocompromised individuals, solitary kidneys, worsening kidney function, AIDS, fever lasting longer than 48 hours, persistent toxicity beyond 72 hours, and lack of response to treatment. The American College of Radiology recommends imaging in these high-risk scenarios.

Abdominal/pelvic CT scan with and without contrast is the preferred imaging modality for acute pyelonephritis. Non-contrast CT scans can effectively detect kidney stones, which can significantly complicate treatment and cannot be reliably excluded based on clinical presentation alone.

• MRI with diffusion-weighted imaging is a valuable alternative for patients with contraindications to intravenous contrast agents and in pregnant women when ultrasound is insufficient. Apparent diffusion coefficient (ADC) values obtained from diffusion-weighted MRI can aid in pyelo diagnosis and help differentiate pyelonephritis from renal abscess.

CT scans are indicated and recommended for high-risk patients to confirm pyelo diagnosis and assess for complications. While renal ultrasound can be performed, CT scanning is generally the preferred imaging method in critical situations due to the limitations of ultrasound in reliably detecting pyelonephritis and associated complications. MRI is a suitable alternative imaging modality when CT is contraindicated.

The vast majority of pyelonephritis cases involve unilateral renal involvement. However, bilateral pyelonephritis can occur with similar symptoms. Patients with bilateral pyelonephritis tend to present with more severe illness, experience more rapid disease progression, are more likely to develop acute kidney injury, and generally have poorer outcomes compared to those with unilateral involvement. Early use of imaging can help distinguish between unilateral and bilateral disease, influencing treatment strategies and prognosis assessment in pyelo diagnosis.

Pregnant patients with acute pyelonephritis require hospital admission due to the increased risk of preterm labor and other complications. Initial evaluation should include ultrasound. If the pyelo diagnosis remains uncertain after ultrasound, and considering that CT scans are generally avoided during pregnancy, MRI or cystoscopy with retrograde pyelography should be considered, especially to rule out obstructive pyelonephritis.

Acute lobar nephronia or acute focal bacterial nephritis is a less common radiological diagnosis considered in patients who clinically appear to have acute pyelonephritis but fail to improve with appropriate antibiotic therapy without an obvious explanation. It is more frequently observed in children than adults.

The pyelo diagnosis of acute lobar nephronia is made by CT scanning, which reveals a mass-like, wedge-shaped, or rounded hypodense renal defect with indistinct borders after intravenous contrast administration. This defect is often poorly visualized on non-contrast images. Ultrasound findings for acute lobar nephronia are not definitive or distinctive. Contrast-enhanced CT (preferred) or intravenous pyelogram are required for diagnosis, but MRI can be used in patients who cannot receive contrast agents.

The defect seen in acute lobar nephronia represents vascular ischemia, typically affecting a wedge-shaped area of the renal parenchyma, resulting from a localized, intense kidney infection without gas, liquefaction, or abscess formation. This condition can rapidly progress (within three days or less) to a renal abscess, characterized by a walled-off cavity with central tissue necrosis. Acute lobar nephronia is more often seen in individuals with diabetes and may be associated with papillary necrosis.

Acute lobar nephronia is generally considered an intermediate stage between acute pyelonephritis and renal abscess. It should be suspected in patients with presumed pyelonephritis who have persistent fever (four or more days in adults, two or more days in children) despite appropriate antibiotic treatment, and in the absence of urinary obstruction or other apparent causes of treatment failure.

Contrast-enhanced CT remains the most reliable imaging modality for pyelo diagnosis of acute lobar nephronia. Ultrasound is not considered adequate, although certain findings like focal loss of corticomedullary differentiation, kidney enlargement (nephromegaly), or a localized, hypoechoic renal mass on ultrasound might suggest the diagnosis.

Treatment for acute lobar nephronia involves prolonged antibiotic therapy, typically four weeks in adults and at least three weeks in children. Following successful antibiotic treatment, the affected renal area may develop a cortical scar.

Obstructive pyelonephritis (pyonephrosis), a surgical emergency requiring urgent drainage of an infected renal pelvis due to urinary calculi obstruction, can be clinically indistinguishable from acute pyelonephritis. Therefore, renal imaging, particularly non-contrast CT scanning, should be considered in at-risk patients to aid in pyelo diagnosis. This includes patients who appear severely ill, exhibit signs or symptoms of sepsis, fail to improve on standard therapy after 48 to 72 hours, have a history of kidney stones, or when obstructive pyelonephritis is clinically suspected.

Ultrasound can sometimes aid in the pyelo diagnosis of obstructive pyelonephritis by demonstrating fluid levels, echogenic debris, and air or gas within the collecting system. However, ultrasound may not always visualize the obstructing calculus. CT scanning may be necessary to identify the cause and location of urinary obstruction, determine the size of ureteral or ureteropelvic junction stones, confirm the pyelo diagnosis, and identify any extrarenal pathology or complications.

Treatment and Management of Acute Pyelonephritis

Healthy, young, non-pregnant women with uncomplicated pyelonephritis can often be treated as outpatients. The cornerstone of acute pyelonephritis treatment includes antibiotics, analgesics for pain relief, and antipyretics to reduce fever. Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for managing both pain and fever associated with acute pyelonephritis. Initial antibiotic selection is empiric, guided by local antibiotic resistance patterns, typically available as antibiograms from hospitals or institutions. Antibiotic therapy should subsequently be tailored based on urine culture and sensitivity results.

E. coli is the most common causative organism in acute pyelonephritis. For E. coli-related infections, oral cephalosporins or sulfamethoxazole-trimethoprim for 14 days, or a fluoroquinolone for a week, are often effective treatment options.

For uncomplicated pyelonephritis, the American College of Physicians recommends sulfamethoxazole-trimethoprim for 14 days or a fluoroquinolone for 5 to 7 days, considering local bacterial resistance patterns and urine culture antibiotic sensitivity results. Most compliant patients with uncomplicated pyelonephritis, without significant comorbidities (>95%), can be treated as outpatients with oral antibiotics after initial evaluation, potentially in the emergency department, and possibly a single parenteral dose of an appropriate antibiotic, often ceftriaxone.

Resistance to sulfamethoxazole-trimethoprim and fluoroquinolones in the US has been reported to be at least 33% and 10%, respectively. Therefore, awareness of local bacterial resistance patterns is crucial when deciding on initial empiric therapy. Fluoroquinolones and sulfamethoxazole/trimethoprim have the advantage of minimally affecting vaginal flora, making them preferable over other agents when bacterial susceptibility is confirmed.

In areas where local bacterial sensitivity data indicates community resistance of 10% or more to a particular antibiotic, the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases recommend administering an initial long-acting parenteral antibiotic (such as aminoglycoside, ertapenem, or ceftriaxone) in the emergency department before discharge. Ertapenem is often reserved for highly resistant cases, and aminoglycosides, while effective, can be nephrotoxic, although a single dose is generally considered safe. Ceftriaxone is frequently the preferred parenteral agent due to its effectiveness and safety profile.

It is essential to have a designated physician responsible for reviewing culture results when available and communicating these findings to the patient, especially regarding any necessary changes in therapy. Therapy should always be streamlined to a narrower-spectrum agent whenever safe and feasible based on culture and sensitivity results.

Fluoroquinolones are generally the preferred oral antibiotic class if the organism is sensitive and can be used empirically in areas with community resistance rates of 10% or less. Sulfamethoxazole-trimethoprim for 14 days or cephalexin for 7 to 10 days can be appropriate in certain situations, but increasing bacterial resistance diminishes their utility for empiric use.

Ceftriaxone is generally a good initial empiric parenteral therapy choice for pyelonephritis. Carbapenems should typically be reserved for critically ill patients or when other agents are not suitable.

A single dose of gentamicin can be considered adjunctively with other selected treatments. Gentamicin achieves high renal tissue concentrations, has minimal impact on kidney function, and has been shown to improve outcomes.

Appropriate empiric antibiotics for outpatients with acute pyelonephritis include:

• If quinolone resistance in community-acquired infections is 10% or less:

  • Fluoroquinolone for 7 days (14 days in male patients)

• If quinolone resistance in community-acquired infections is greater than 10%, choose one of the following (assuming bacterial sensitivity):

  • Amoxicillin-clavulanate 875 mg orally twice daily for 7 to 10 days
  • Cefpodoxime 200 mg orally twice daily for 7 to 10 days
  • Cefadroxil 1 g orally twice daily for 7 to 10 days
  • Sulfamethoxazole-trimethoprim for 14 days

Follow-up assessment should occur within 24 to 48 hours after discharge to evaluate symptom resolution and adjust therapy if needed. Uncomplicated cases with complete symptom resolution typically do not require imaging or follow-up urine cultures. If identifying an appropriate oral antimicrobial agent based on bacterial cultures is challenging due to resistance, allergies, or other factors, consultation with an infectious disease specialist is recommended.

Indications for inpatient care include overt signs of sepsis, high fever, significant or poorly controlled pain, persistent nausea (limiting oral hydration and medication), marked debility, outpatient treatment failure, significant comorbidities, likelihood of therapy non-compliance, and inadequate home care support. Patients who are immunocompromised, kidney transplant recipients, have poorly controlled diabetes, are pregnant, or are suspected of urinary tract obstruction should also be hospitalized. Approximately 20% of all patients with acute pyelonephritis require inpatient treatment.

Intolerance of oral medications or lack of suitable oral antibiotics necessitates parenteral treatment, but this does not always require inpatient hospitalization, depending on the feasibility and appropriateness of home IV therapy.

Acute pyelonephritis complicated by ureteral obstruction, often due to ureterolithiasis, constitutes obstructive pyelonephritis or pyonephrosis. This is a surgical emergency requiring immediate surgical drainage via a double J stent or percutaneous nephrostomy, along with targeted antibiotic therapy. Delaying emergency drainage procedures until the patient is “stable” for surgery is not advised. Postponing surgery by 48 hours or more increases mortality risk significantly. These patients are frequently septic and require hospitalization.

Appropriate empiric antibiotics for inpatients with acute pyelonephritis include:

• An antipseudomonal carbapenem (imipenem or meropenem) plus vancomycin (for critically ill patients)
• Ceftriaxone (generally preferred for most cases)
• Fluoroquinolone (depending on local resistance patterns)
• Piperacillin-tazobactam (preferred for suspected Enterococcus or Pseudomonas)
• Cefepime (not for ESBL-producing bacteria)
• Cefotaxime
• Cefuroxime
• Ceftazidime
• Aztreonam
• Aminoglycosides (gentamicin, tobramycin, or amikacin)
• An antipseudomonal carbapenem (if recent ESBL bacterial isolate is identified)

PLUS

• Add vancomycin or linezolid if a Gram-positive organism is suspected.

Intravenous antibiotics are typically administered for at least 48 hours, by which time culture results are usually available, and patients should show a positive clinical response.

• For patients responding well, consider switching to appropriate oral antibiotic therapy, as this has demonstrated equivalent outcomes to continued parenteral therapy.

• If no improvement is observed, consider changing antibiotics, continuing parenteral therapy, and obtaining appropriate imaging if not already performed. Urology consultation should be considered if imaging reveals obstruction, or infectious disease consultation if imaging is negative.

Septic patients require hospital admission for parenteral therapy and appropriate imaging. Antibiotic therapy generally continues for 10 to 14 days. Consulting local infectious disease specialists for guidance on empiric therapy for pyelonephritis is a reasonable approach.

Preferred antibiotics for treating pyelonephritis in pregnant patients, according to the American College of Obstetricians and Gynecologists Clinical Consensus Statement, include ampicillin-sulbactam or ampicillin plus optional gentamicin, cefepime, ceftriaxone, or aztreonam (in penicillin-allergic patients). Data on carbapenem use in pregnancy is limited, so they are not routinely recommended in the US, although their use is permitted in Europe.

Cefotaxime, ceftazidime, and piperacillin-tazobactam can also be considered based on local resistance patterns and individual patient factors. Treatment should commence immediately, without waiting for culture results, and continue for 14 days. Antibiotics should be adjusted based on culture results and clinical improvement. Fluoroquinolones, nitrofurantoin, and fosfomycin should be avoided for pyelonephritis treatment during pregnancy.

Post-pyelonephritis prophylaxis with nitrofurantoin 100 mg or cephalexin 250 mg to 500 mg daily may be considered, as recurrent pyelonephritis can occur in up to 25% of pregnant patients. Prophylaxis, if initiated, should continue throughout pregnancy and for an additional 4 to 6 weeks postpartum.

Procalcitonin levels can help optimize the duration of antibiotic therapy. A multicenter randomized study showed that a procalcitonin reduction of at least 80% or to a level below 0.5 μg/L by day 5 or later after admission was medically and clinically sufficient, more cost-effective, reduced hospital stay duration, and lowered antibiotic-related complications like pseudomembranous colitis compared to standard therapy.

Complicated cases, patients with increased infection risk, and all patients hospitalized or receiving parenteral antibiotics should have follow-up urine cultures 1 to 2 weeks after therapy completion. Imaging should be considered if not previously performed. Monthly urine cultures have been suggested for selected high-risk patients.

Treatment for highly resistant infections may include the following, guided by local resistance patterns and individual culture sensitivity results:

• Aminoglycosides (amikacin, gentamicin, tobramycin)
• Aztreonam
• Aztreonam-avibactam
• Carbapenems
• Cefepime
• Cefiderocol
• Cefotaxime
• Cefpodoxime
• Ceftazidime-avibactam
• Ceftriaxone
• Chloramphenicol
• Daptomycin
• Fluoroquinolones
• Linezolid
• Meropenem-vaborbactam
• Piperacillin-tazobactam
• Tigecycline

Fosfomycin is frequently used for UTIs due to its continued effectiveness against multidrug-resistant infections, but its use in pyelonephritis is debated. In the United States, it is not officially recommended or approved for pyelonephritis due to concerns about inadequate renal tissue and serum levels, despite achieving high urine concentrations. However, it has been used successfully in pyelonephritis cases and may be considered off-label in selected situations.

Due to its high urine levels and relative resistance to bacterial resistance mechanisms, fosfomycin may be a suitable oral step-down therapy after initial parenteral antibiotics like ertapenem for outpatient management. Fosfomycin is not routinely included in bacterial culture sensitivity reports but can be specifically requested. While generally safe, fosfomycin is not recommended for pyelonephritis treatment during pregnancy.

Aminoglycosides are relatively underutilized in pyelonephritis treatment. A single aminoglycoside dose can improve outcomes and survival, and should be considered in sicker or high-risk patients. Aminoglycosides achieve high renal tissue levels, can be used in combination with other antimicrobials, act synergistically with many antibiotics (including beta-lactams and carbapenems), reduce mortality, and improve outcomes in serious kidney infections without causing significant nephrotoxicity when used appropriately. Aminoglycoside-based treatment can also help reduce carbapenem overuse. Adhering to proper dosing guidelines and recommended protocols for ongoing treatment is crucial.

Reducing antibiotic resistance is a shared responsibility for all prescribing physicians. Urinary tract infections account for up to 40% of all antibiotics prescribed globally. Initial UTI management can often focus on symptomatic relief until culture-specific results and sensitivities become available, typically within 48 hours. The risk of uncomplicated UTI progressing to pyelonephritis is relatively low, only 1% to 2%.

Avoiding overuse of broad-spectrum antibiotics in uncomplicated UTIs can help mitigate bacterial antibiotic resistance. The majority of uncomplicated UTIs can be effectively managed with nitrofurantoin, fosfomycin, or pivmecillinam, with treatment durations of 3 to 5 days generally sufficient.

Pivmecillinam is currently under FDA review for UTI treatment in the US. It has been available in Europe, Scandinavia, and Canada for over 40 years, demonstrating a 95% cure rate for cystitis with minimal resistance reported. Bacterial resistance to pivmecillinam remains low (5% or less), even in regions with frequent use. It has a unique bactericidal mechanism, inhibiting penicillin-binding protein 2. Pivmecillinam achieves high renal tissue concentrations and may be suitable for pyelonephritis treatment, with an intravenous formulation also available.

Modifying the approach to uncomplicated UTI treatment, prioritizing symptomatic management when possible until culture results are available, and using preferred first-line agents (nitrofurantoin, fosfomycin, or pivmecillinam) when appropriate for no more than seven days, can contribute to reducing bacterial antibiotic resistance and improving patient outcomes. Improved point-of-care rapid diagnostic testing can further enhance antibiotic stewardship.

Differential Diagnosis of Acute Pyelonephritis

When considering a pyelo diagnosis, it is prudent to maintain a broad differential diagnosis initially. Physicians should consider other conditions in patients presenting with fever, flank pain, and costovertebral angle tenderness. Given the variability in symptoms (unilateral, bilateral, radiating, sharp, dull) and the potential for pyelonephritis to progress to sepsis and shock, the differential diagnoses can be extensive.

Common conditions mimicking acute pyelonephritis include:

• Appendicitis
• Cholecystitis
• Costochondritis
• Diverticulitis
• Ectopic pregnancy
• Endometritis
• Focal nephronia
• Herpes zoster
• Lobar pneumonia
• Nephrolithiasis
• Ovarian cyst pathology
• Pancreatitis
• Pelvic inflammatory disease
• Perinephric abscess
• Pyonephrosis (obstructive pyelonephritis)
• Renal abscess
• Rib fracture
• Ureterolithiasis
• Ureteropelvic junction obstruction
• Urolithiasis
• Xanthogranulomatous pyelonephritis

Prognosis of Acute Pyelonephritis

Most cases of pyelonephritis (80%) are managed in outpatient settings, with the majority of patients improving with oral antibiotics, anti-inflammatories, and antipyretics. Young, healthy women with uncomplicated pyelonephritis are most likely to be treated as outpatients.

Uncomplicated pyelonephritis is not typically considered a dangerous or lethal condition unless complicated by secondary conditions like emphysematous pyelonephritis, perinephric abscess, pyonephrosis, or sepsis. In such complicated cases, mortality rates of 25% or higher have been reported, but outcomes are greatly influenced by disease severity, patient comorbidities, early pyelo diagnosis, bacterial resistance patterns, and timely initiation of appropriate antibiotic therapy.

Despite generally favorable outcomes in most pyelonephritis cases, severe or complicated cases still carry significant morbidity and mortality risks.

Pregnant women with acute pyelonephritis are at a particularly high risk for premature delivery, as well as other complications such as acute respiratory distress syndrome, acute renal injury, sepsis, intrauterine growth restriction, and even fetal death.

Overall mortality rates for acute pyelonephritis have been reported in the range of 10% to 20% in some studies, with a recent study from Hong Kong reporting a mortality rate closer to 7.4%.

Increased mortality risk is associated with older age (over 65 years), diabetes, kidney failure, disseminated intravascular coagulation, sepsis (septic shock), long-term indwelling catheters, limited mobility (bedridden status), and male gender.

With early recognition of the underlying cause and prompt intervention with appropriate treatment, even patients with severe pyelonephritis generally have a good prognosis.

Early initiation of appropriate antibiotic therapy improves outcomes and can be life-saving in acute pyelonephritis.

Complications of Acute Pyelonephritis

Acute pyelonephritis can lead to several complications, with emphysematous pyelonephritis being one of the most serious.

Emphysematous pyelonephritis is a severe, necrotizing kidney infection typically caused by E. coli or Klebsiella pneumoniae. It is a serious complication of acute pyelonephritis, more commonly seen in diabetic patients and more frequently in women. Ultrasound can suggest the pyelo diagnosis, but CT is usually needed for confirmation. The mortality rate of emphysematous pyelonephritis is estimated to be around 38%, with better outcomes associated with combined medical and surgical management compared to medical management alone.

Other complications of acute pyelonephritis include:

• Acute focal nephronia (Acute focal bacterial nephritis)
• Acute renal failure
• Chronic pyelonephritis
• Obstructive pyelonephritis
• Papillary necrosis
• Perinephric abscess
• Renal abscess
• Renal scarring and atrophy
• Renal vein thrombosis
• Sepsis and urosepsis
• Xanthogranulomatous pyelonephritis

Consultations for Acute Pyelonephritis

Most uncomplicated cases of acute pyelonephritis do not require specialist consultations. However, complicated cases may benefit from consultations with urology, obstetrics and gynecology, pediatrics, and infectious diseases specialists.

• Urology consultation is usually indicated for patients with ureteral obstruction, hydronephrosis, urolithiasis, urogenital abnormalities, failed initial therapies, or the first episode of pyelonephritis in an infant.

• Obstetrics and gynecology consultation is recommended for any pregnant patient with acute pyelonephritis.

• Infectious disease consultation is advisable for immunocompromised patients, infections with multidrug-resistant pathogens, failures of initial appropriate therapy, persistently positive blood cultures beyond 48 hours, sepsis, multiple antimicrobial drug allergies, or other comorbidities complicating optimal antibiotic selection. Clinicians should not hesitate to consult an infectious disease specialist for any difficult, complex, severe, or intractable pyelonephritis cases.

Deterrence and Patient Education for Pyelonephritis Prevention

For healthy, young, premenopausal women, preventing UTIs is the most effective strategy to avoid acute pyelonephritis. While various factors can contribute to UTIs, simple preventative measures include voiding before and immediately after sexual intercourse, increasing fluid intake to promote urine volume, and wiping from front to back after urination and defecation, avoiding folding or reusing toilet paper or wipes. These practices help reduce bacterial introduction into the urethra and bladder.

Beyond behavioral interventions, studies have explored the potential benefits of cranberry juice, probiotics, D-mannose, methenamine, vitamin C, and low-dose prophylactic antibiotics in UTI prevention.

To prevent recurrent acute pyelonephritis, patients must complete the full course of prescribed antibiotics and adhere to the prescribed dosage and frequency. Increasing water intake helps prevent dehydration, reduces UTI risk by regularly flushing the bladder, aids in preventing acute pyelonephritis, and supports overall kidney function.

Pearls and Other Key Issues in Pyelo Diagnosis and Management

Key points to remember regarding acute pyelonephritis:

• Acute pyelonephritis typically presents with fever, flank pain, and nausea or vomiting, but not all symptoms need to be present for pyelo diagnosis.

• Pyelo diagnosis is primarily clinical; imaging is not routinely needed but should be considered in high-risk cases or when urolithiasis is suspected.

• Ultrasound can detect pyelonephritis, but a negative ultrasound does not exclude the diagnosis.

• Uncomplicated acute pyelonephritis is often caused by E. coli, treatable with oral cephalosporins, quinolones, or TMP-SMX, guided by community resistance patterns and culture results.

• Always obtain urine cultures before initiating antibiotics.

• Consider catheterized urine specimens if clean-voided samples are contaminated.

• A designated physician should be responsible for reviewing urine cultures, communicating with the patient, and adjusting therapy accordingly.

• Select the narrowest spectrum antimicrobial agent possible once culture results are available.

• Transition to an appropriate oral agent as soon as feasible after culture results and clinical improvement.

• Avoid nitrofurantoin or other antimicrobials with inadequate tissue levels as step-down therapy after parenteral treatment, even if culture results indicate sensitivity.

• Consider empiric use of a single aminoglycoside dose in sicker patients in addition to other selected treatments. Single-dose aminoglycosides are well-tolerated, have minimal transient nephrotoxicity, provide high renal tissue levels, reduce mortality, and improve overall outcomes.

• Utilize the neutrophil-to-lymphocyte ratio as an accessible early marker of sepsis. Ratios greater than 5 suggest sepsis.

• When treatment fails, obtain imaging (usually CT scan) and seek consultation from urology and/or infectious disease specialists.

• Older age (>65 years), male gender, impaired renal function, sepsis, and disseminated intravascular coagulation are associated with increased mortality risk.

• Do not hesitate to consult an infectious disease specialist in complex cases. Optimal antibiotic selection can be challenging due to increasing bacterial resistance, patient allergies and tolerability, drug interactions, renal function, and other factors.

Enhancing Healthcare Team Outcomes in Pyelonephritis Management

Optimal management of acute pyelonephritis requires a collaborative healthcare team, including primary care providers, emergency room specialists, nephrologists, infectious disease consultants, pain specialists, internists, urologists, and obstetricians for pregnant patients. Nurses and pharmacists are crucial for patient monitoring, antibiotic administration, tracking clinical progress, and therapy adjustments as needed. Dietary consultation may be considered for patients with diabetes, but adequate oral hydration is key for all patients.

In cases of reinfection within 14 days of discharge, investigation for underlying anatomical or functional abnormalities is warranted. Urology consultation is indicated if such anomalies (e.g., vesicoureteral reflux, urolithiasis, bladder diverticula, incomplete bladder emptying) are identified. Abdominal and pelvic CT scan with and without IV contrast, post-void residual volume measurement, and careful review of patient medical and surgical history are typically performed.

Pharmacists, infectious disease specialists, and the primary treating physician must ensure antibiotic prescriptions are based on culture results and that patients receive appropriate drugs to target the causative organisms. Pharmacists also play a role in avoiding nephrotoxic agents that could worsen renal damage.

Outcomes

Prompt pyelo diagnosis and treatment are crucial for improving outcomes in patients with acute pyelonephritis. Any delay in initiating treatment can lead to significant morbidity. Even short delays in appropriate management can result in prolonged hospitalizations, unnecessary pain, and potential disability.

Appropriate follow-up after discharge is essential to ensure complete recovery and address any correctable anatomical predisposing factors.

Review Questions

(Note: Review questions are omitted as per instructions to only include title and content)

References

(References are included as in the original article)

1. Johnson JR, Russo TA. Acute Pyelonephritis in Adults. N Engl J Med. 2018 Jan 04;378(1):48-59. [PubMed: 29298155]
2. Guarino N, Casamassima MG, Tadini B, Marras E, Lace R, Bianchi M. Natural history of vesicoureteral reflux associated with kidney anomalies. Urology. 2005 Jun;65(6):1208-11. [PubMed: 15913724]
3. Jha SK, Leslie SW, Aeddula NR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 6, 2024. Xanthogranulomatous Pyelonephritis. [PubMed: 32491331]
4. Ciccarese F, Brandi N, Corcioni B, Golfieri R, Gaudiano C. Complicated pyelonephritis associated with chronic renal stone disease. Radiol Med. 2021 Apr;126(4):505-516. [PMC free article: PMC8007507] [PubMed: 33245481]
5. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84. [PMC free article: PMC4457377] [PubMed: 25853778]
6. Choong FX, Antypas H, Richter-Dahlfors A. Integrated Pathophysiology of Pyelonephritis. Microbiol Spectr. 2015 Oct;3(5) [PubMed: 26542040]
7. Bono MJ, Leslie SW, Reygaert WC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections. [PubMed: 29261874]
8. Pasiechnikov S, Buchok O, Sheremeta R, Banyra O. Empirical treatment in patients with acute obstructive pyelonephritis. Infect Disord Drug Targets. 2015;15(3):163-70. [PubMed: 26321323]
9. Lotfollahzadeh S, Leslie SW, Aeddula NR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 30, 2024. Vesicoureteral Reflux. [PubMed: 33085409]
10. Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, deBerardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, Viteri B, Egigueron M, Shah N, Hoberman A. Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring. Pediatrics. 2015 Jul;136(1):e13-21. [PMC free article: PMC4485012] [PubMed: 26055855]
11. Graversen ME, Dalgaard LS, Jensen-Fangel S, Jespersen B, Østergaard L, Søgaard OS. Risk and outcome of pyelonephritis among renal transplant recipients. BMC Infect Dis. 2016 Jun 10;16:264. [PMC free article: PMC4901406] [PubMed: 27287058]
12. Sabih A, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Complicated Urinary Tract Infections. [PubMed: 28613784]
13. Habboush Y, Guzman N. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 20, 2023. Antibiotic Resistance. [PubMed: 30020649]
14. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000 Jan;30(1):14-8. [PubMed: 10619726]
15. Alvarez-Lerma F, Nolla-Salas J, León C, Palomar M, Jordá R, Carrasco N, Bobillo F., EPCAN Study Group. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 2003 Jul;29(7):1069-76. [PubMed: 12756441]
16. Colodner R, Nuri Y, Chazan B, Raz R. Community-acquired and hospital-acquired candiduria: comparison of prevalence and clinical characteristics. Eur J Clin Microbiol Infect Dis. 2008 Apr;27(4):301-5. [PubMed: 18097694]
17. Bougnoux ME, Kac G, Aegerter P, d’Enfert C, Fagon JY., CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008 Feb;34(2):292-9. [PubMed: 17909746]
18. Irby PB, Stoller ML, McAninch JW. Fungal bezoars of the upper urinary tract. J Urol. 1990 Mar;143(3):447-51. [PubMed: 2304151]
19. Das MK, Rangrajan Pakshi R, Kalra S, Elumalai A, Theckumparampil N. Fungal Balls Mimicking Renal Calculi: A Zebra Among Horses. J Endourol Case Rep. 2019;5(4):167-170. [PMC free article: PMC7383421] [PubMed: 32775655]
20. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ., EMERGEncy ID Net Study Group. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerg Infect Dis. 2016 Sep;22(9):1594-603. [PMC free article: PMC4994338] [PubMed: 27532362]
21. Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013 Sep;34(9):940-6. [PubMed: 23917908]
22. Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin Infect Dis. 2013 Nov;57(9):1266-9. [PMC free article: PMC7314120] [PubMed: 23926177]
23. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR., VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013 Nov;57(9):1256-65. [PMC free article: PMC3792724] [PubMed: 23926176]
24. Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Emerg Med Int. 2013;2013:258517. [PMC free article: PMC3844142] [PubMed: 24307946]
25. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1148-52. [PubMed: 15150380]
26. Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis. 2016 Oct 01;63(7):960-5. [PubMed: 27313263]
27. Smithson A, Chico C, Ramos J, Netto C, Sanchez M, Ruiz J, Porron R, Bastida MT. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):423-30. [PubMed: 21761126]
28. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs. 1998 Mar;55(3):323-30. [PubMed: 9530540]
29. Trautner BW, Kaye KS, Gupta V, Mulgirigama A, Mitrani-Gold FS, Scangarella-Oman NE, Yu K, Ye G, Joshi AV. Risk Factors Associated With Antimicrobial Resistance and Adverse Short-Term Health Outcomes Among Adult and Adolescent Female Outpatients With Uncomplicated Urinary Tract Infection. Open Forum Infect Dis. 2022 Dec;9(12):ofac623. [PMC free article: PMC10101691] [PubMed: 37065971]
30. Mitrani-Gold FS, Kaye KS, Gupta V, Mulgirigama A, Trautner BW, Scangarella-Oman NE, Yu KC, Ye G, Joshi AV. Older patient age and prior antimicrobial use strongly predict antimicrobial resistance in Escherichia coli isolates recovered from urinary tract infections among female outpatients. PLoS One. 2023;18(5):e0285427. [PMC free article: PMC10174568] [PubMed: 37167277]
31. Chen Q, Li D, Beiersmann C, Neuhann F, Moazen B, Lu G, Müller O. Risk factors for antibiotic resistance development in healthcare settings in China: a systematic review. Epidemiol Infect. 2021 Jun 03;149:e141. [PMC free article: PMC8220497] [PubMed: 34078502]
32. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE., Infectious Diseases Society of America. European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 01;52(5):e103-20. [PubMed: 21292654]
33. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016 Sep 15;63(6):754-762. [PMC free article: PMC4996135] [PubMed: 27313268]
34. Shrestha J, Zahra F, Cannady, Jr P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 20, 2023. Antimicrobial Stewardship. [PubMed: 34283434]
35. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017;6:47. [PMC free article: PMC5433038] [PubMed: 28515903]
36. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019 Jan-Dec;11:1756287219832172. [PMC free article: PMC6502976] [PubMed: 31105774]
37. Jansåker F, Li X, Vik I, Frimodt-Møller N, Knudsen JD, Sundquist K. The Risk of Pyelonephritis Following Uncomplicated Cystitis: A Nationwide Primary Healthcare Study. Antibiotics (Basel). 2022 Nov 24;11(12) [PMC free article: PMC9774091] [PubMed: 36551352]
38. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003 Feb;13(2):144-50. [PubMed: 12559674]
39. Svingel LS, Christiansen CF, Birn H, Søgaard KK, Nørgaard M. Temporal changes in incidence of hospital-diagnosed acute pyelonephritis: A 19-year population-based Danish cohort study. IJID Reg. 2023 Dec;9:104-110. [PMC free article: PMC10656209] [PubMed: 38020186]
40. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007 Aug 01;45(3):273-80. [PubMed: 17599303]
41. Ansaldi Y, Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023 Oct;29(10):1249-1253. [PubMed: 36031053]
42. Angelescu K, Nussbaumer-Streit B, Sieben W, Scheibler F, Gartlehner G. Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review. BMC Pregnancy Childbirth. 2016 Nov 02;16(1):336. [PMC free article: PMC5093995] [PubMed: 27806709]
43. Kazemier BM, Koningstein FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, Vogelvang TE, Verhoeven CJ, Langenveld J, Woiski M, Oudijk MA, van der Ven JE, Vlegels MT, Kuiper PN, Feiertag N, Pajkrt E, de Groot CJ, Mol BW, Geerlings SE. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis. 2015 Nov;15(11):1324-33. [PubMed: 26255208]
44. Ruiz-Rosado JD, Robledo-Avila F, Cortado H, Rangel-Moreno J, Justice SS, Yang C, Spencer JD, Becknell B, Partida-Sanchez S. Neutrophil-Macrophage Imbalance Drives the Development of Renal Scarring during Experimental Pyelonephritis. J Am Soc Nephrol. 2021 Jan;32(1):69-85. [PMC free article: PMC7894670] [PubMed: 33148615]
45. Li B, Haridas B, Jackson AR, Cortado H, Mayne N, Kohnken R, Bolon B, McHugh KM, Schwaderer AL, Spencer JD, Ching CB, Hains DS, Justice SS, Partida-Sanchez S, Becknell B. Inflammation drives renal scarring in experimental pyelonephritis. Am J Physiol Renal Physiol. 2017 Jan 01;312(1):F43-F53. [PMC free article: PMC5283888] [PubMed: 27760770]
46. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Acute Pyelonephritis. Am J Kidney Dis. 2016 Oct;68(4):e21-e22. [PubMed: 27664480]
47. Khoo KSM, Lim ZY, Chai CY, Mahadevan M, Kuan WS. Management of acute pyelonephritis in the emergency department observation unit. Singapore Med J. 2021 Jun;62(6):287-295. [PMC free article: PMC8801831] [PubMed: 32147739]
48. Urinary Tract Infections in Pregnant Individuals. Obstet Gynecol. 2023 Aug 01;142(2):435-445. [PubMed: 37473414]
49. Chen Y, Nitzan O, Saliba W, Chazan B, Colodner R, Raz R. Are blood cultures necessary in the management of women with complicated pyelonephritis? J Infect. 2006 Oct;53(4):235-40. [PubMed: 16434102]
50. Papava V, Didbaridze T, Zaalishvili Z, Gogokhia N, Maziashvili G. The Role of Urinary Nitrite in Predicting Bacterial Resistance in Urine Culture Analysis Among Patients With Uncomplicated Urinary Tract Infection. Cureus. 2022 Jun;14(6):e26032. [PMC free article: PMC9291437] [PubMed: 35865430]
51. Arambašić J, Mandić S, Debeljak Ž, Mandić D, Horvat V, Šerić V. Differentiation of acute pyelonephritis from other febrile states in children using urinary neutrophil gelatinase-associated lipocalin (uNGAL). Clin Chem Lab Med. 2016 Jan;54(1):55-61. [PubMed: 26053013]
52. Moon JH, Yoo KH, Yim HE. Urinary neutrophil gelatinase-associated lipocalin: a marker of urinary tract infection among febrile children. Clin Exp Pediatr. 2021 Jul;64(7):347-354. [PMC free article: PMC8255512] [PubMed: 33091975]
53. Yamamoto A, Nakayama S, Wakabayashi Y, Yoshino Y, Kitazawa T. Urine neutrophil gelatinase-associated lipocalin as a biomarker of adult pyelonephritis. J Infect Chemother. 2023 May;29(5):508-512. [PubMed: 36621764]
54. Shaikh K, Rajakumar V, Osio VA, Shaikh N. Neutrophil gelatinase-associated lipocalin for urinary tract infection and pyelonephritis: a systematic review. Pediatr Nephrol. 2021 Jun;36(6):1481-1487. [PubMed: 33389090]
55. Fulton II MR, Zubair M, Taghavi S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 27, 2023. Laboratory Evaluation of Sepsis. [PubMed: 37603649]
56. Gürol G, Çiftci İH, Terizi HA, Atasoy AR, Ozbek A, Köroğlu M. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? J Microbiol Biotechnol. 2015 Apr;25(4):521-5. [PubMed: 25341467]
57. Martins EC, Silveira LDF, Viegas K, Beck AD, Fioravantti Júnior G, Cremonese RV, Lora PS. Neutrophil-lymphocyte ratio in the early diagnosis of sepsis in an intensive care unit: a case-control study. Rev Bras Ter Intensiva. 2019;31(1):64-70. [PMC free article: PMC6443306] [PubMed: 30916236]
58. Cleland DA, Eranki AP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 23, 2023. Procalcitonin. [PubMed: 30969616]
59. Nehring SM, Goyal A, Patel BC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. C Reactive Protein. [PubMed: 28722873]
60. Expert Panel on Urological Imaging. Smith AD, Nikolaidis P, Khatri G, Chong ST, De Leon AD, Ganeshan D, Gore JL, Gupta RT, Kwun R, Lyshchik A, Nicola R, Purysko AS, Savage SJ, Taffel MT, Yoo DC, Delaney EW, Lockhart ME. ACR Appropriateness Criteria® Acute Pyelonephritis: 2022 Update. J Am Coll Radiol. 2022 Nov;19(11S):S224-S239. [PubMed: 36436954]
61. Yu J, Sri-Ganeshan M, Smit V, Mitra B. Ultrasound for acute pyelonephritis: a systematic review and meta-analysis. Intern Med J. 2024 Jul;54(7):1106-1118. [PubMed: 38339768]
62. Pinto DS, George A, Johny J, Hoisala RV. Role of MRI in the evaluation of acute pyelonephritis in a high-risk population with renal dysfunction: a prospective study. Emerg Radiol. 2023 Jun;30(3):285-295. [PubMed: 36959518]
63. El-Ghar MA, Farg H, Sharaf DE, El-Diasty T. CT and MRI in Urinary Tract Infections: A Spectrum of Different Imaging Findings. Medicina (Kaunas). 2021 Jan 01;57(1) [PMC free article: PMC7824127] [PubMed: 33401464]
64. Rathod SB, Kumbhar SS, Nanivadekar A, Aman K. Role of diffusion-weighted MRI in acute pyelonephritis: a prospective study. Acta Radiol. 2015 Feb;56(2):244-9. [PubMed: 24443116]
65. Lee A, Kim HC, Hwang SI, Chin HJ, Na KY, Chae DW, Kim S. Clinical Usefulness of Unenhanced Computed Tomography in Patients with Acute Pyelonephritis. J Korean Med Sci. 2018 Sep 17;33(38):e236. [PMC free article: PMC6137028] [PubMed: 30224907]
66. Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int. 2011 May;107(9):1474-8. [PubMed: 20840327]
67. Sherchan R, Hamill R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 11, 2024. Emphysematous Pyelonephritis. [PubMed: 38261674]
68. Vernuccio F, Patti D, Cannella R, Salvaggio G, Midiri M. CT imaging of acute and chronic pyelonephritis: a practical guide for emergency radiologists. Emerg Radiol. 2020 Oct;27(5):561-567. [PubMed: 32445022]
69. Ha SK, Seo JK, Kim SJ, Park SH, Park CH, Lee HY, Han DS, Kim KW. Acute pyelonephritis focusing on perfusion defects on contrast enhanced computerized tomography(CT) scans and its clinical outcome. Korean J Intern Med. 1997 Jun;12(2):122-7. [PMC free article: PMC4531993] [PubMed: 9439146]
70. Mainali A, Adhikari S, Chowdhury T, Gousy N, Uprety N, Arora A, Palencia CJ. Acute Non-Obstructive Bilateral Pyelonephritis With Acute Kidney Injury Requiring Hemodialysis. Cureus. 2022 Jul;14(7):e26746. [PMC free article: PMC9365028] [PubMed: 35967161]
71. Guvvala SL, Sakam S, Stokes MB, Uday K. Bilateral acute non-obstructive pyelonephritis presenting as acute kidney injury requiring haemodialysis. BMJ Case Rep. 2019 Feb 21;12(2) [PMC free article: PMC6389091] [PubMed: 30796082]
72. Lee YJ, Cho S, Kim SR. Unilateral and bilateral acute pyelonephritis: differences in clinical presentation, progress and outcome. Postgrad Med J. 2014 Feb;90(1060):80-5. [PubMed: 24255118]
73. Jiao S, Yan Z, Zhang C, Li J, Zhu J. Clinical features of acute focal bacterial nephritis in adults. Sci Rep. 2022 May 04;12(1):7292. [PMC free article: PMC9068887] [PubMed: 35508538]
74. Rosenfield AT, Glickman MG, Taylor KJ, Crade M, Hodson J. Acute focal bacterial nephritis (acute lobar nephronia). Radiology. 1979 Sep;132(3):553-61. [PubMed: 382239]
75. Huang JJ, Sung JM, Chen KW, Ruaan MK, Shu GH, Chuang YC. Acute bacterial nephritis: a clinicoradiologic correlation based on computed tomography. Am J Med. 1992 Sep;93(3):289-98. [PubMed: 1524081]
76. Hosokawa T, Tanami Y, Sato Y, Oguma E. Comparison of imaging findings between acute focal bacterial nephritis (acute lobar nephronia) and acute pyelonephritis: a preliminary evaluation of the sufficiency of ultrasound for the diagnosis of acute focal bacterial nephritis. Emerg Radiol. 2020 Aug;27(4):405-412. [PubMed: 32162084]
77. Patel H, Shekar Paulraj A, Anand B. Thinking of Draining a Renal Abscess? Wait! – Could Be Acute Lobar Nephronia. Urology. 2021 Oct;156:e90-e92. [PubMed: 34302834]
78. Fujita Y, Imataka G, Kuwashima S, Yoshihara S. Magnetic resonance imaging diagnosis of acute focal bacterial nephritis with MERS. Pediatr Int. 2020 Sep;62(9):1121-1122. [PubMed: 33000563]
79. Yılmaz K, Koç G, Yel S, Dursun İ, Doğanay S. Acute lobar nephronia: value of unique magnetic resonance imaging findings in diagnosis and management. Turk J Pediatr. 2015 Jan-Feb;57(1):105-8. [PubMed: 26613232]
80. Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am. 1997 Sep;11(3):663-80. [PubMed: 9378929]
81. Oka H, Nagamori T, Yamamoto S, Manabe H, Taketazu G, Mukai T, Sakata H, Oki J. Non-invasive discrimination of acute focal bacterial nephritis with pyelonephritis. Pediatr Int. 2019 Aug;61(8):777-780. [PubMed: 31410918]
82. Kline MW, Kaplan SL, Baker CJ. Acute focal bacterial nephritis: diverse clinical presentations in pediatric patients. Pediatr Infect Dis J. 1988 May;7(5):346-9. [PubMed: 3288948]
83. Cheng CH, Tsau YK, Hsu SY, Lee TL. Effective ultrasonographic predictor for the diagnosis of acute lobar nephronia. Pediatr Infect Dis J. 2004 Jan;23(1):11-4. [PubMed: 14743039]
84. Seidel T, Kuwertz-Bröking E, Kaczmarek S, Kirschstein M, Frosch M, Bulla M, Harms E. Acute focal bacterial nephritis in 25 children. Pediatr Nephrol. 2007 Nov;22(11):1897-901. [PubMed: 17874139]
85. Dubey D, Raza FS, Sawhney A, Pandey A. Klebsiella pneumoniae Renal Abscess Syndrome: A Rare Case with Metastatic Involvement of Lungs, Eye, and Brain. Case Rep Infect Dis. 2013;2013:685346. [PMC free article: PMC3748422] [PubMed: 23984128]
86. Linder BJ, Granberg CF. Pediatric renal abscesses: A contemporary series. J Pediatr Urol. 2016 Apr;12(2):99.e1-5. [PubMed: 26522771]
87. Nicola R, Menias CO. Urinary Obstruction, Stone Disease, and Infection. In: Hodler J, Kubik-Huch RA, von Schulthess GK, editors. Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging – IDKD Book [Internet]. Springer; Cham (CH): Mar 21, 2018. pp. 223–228. [PubMed: 31314368]
88. Tamburrini S, Lugarà M, Iannuzzi M, Cesaro E, De Simone F, Del Biondo D, Toto R, Iulia D, Marrone V, Faella P, Liguori C, Marano I. Pyonephrosis Ultrasound and Computed Tomography Features: A Pictorial Review. Diagnostics (Basel). 2021 Feb 17;11(2) [PMC free article: PMC7921924] [PubMed: 33671431]
89. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians. Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-827. [PubMed: 33819054]
90. Ward G, Jorden RC, Severance HW. Treatment of pyelonephritis in an observation unit. Ann Emerg Med. 1991 Mar;20(3):258-61. [PubMed: 1996820]
91. Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother. 2019 Jan;63(1) [PMC free article: PMC6325212] [PubMed: 30397061]
92. Block M, Blanchard DL. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Aminoglycosides. [PubMed: 31082149]
93. Liljedahl Prytz K, Prag M, Fredlund H, Magnuson A, Sundqvist M, Källman J. Antibiotic treatment with one single dose of gentamicin at admittance in addition to a β-lactam antibiotic in the treatment of community-acquired bloodstream infection with sepsis. PLoS One. 2020;15(7):e0236864. [PMC free article: PMC7392313] [PubMed: 32730359]
94. Cobussen M, de Kort JM, Dennert RM, Lowe SH, Stassen PM. No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis. Infect Dis (Lond). 2016 Apr;48(4):274-280. [PubMed: 26567531]
95. Cobussen M, Haeseker MB, Stoffers J, Wanrooij VHM, Savelkoul PHM, Stassen PM. Renal safety of a single dose of gentamicin in patients with sepsis in the emergency department. Clin Microbiol Infect. 2020 Jul 01; [PubMed: 32621972]
96. Mohsenpour B, Ahmadi A, Azizzadeh H, Ghaderi E, Hajibagheri K, Afrasiabian S, Lotfi G, Farzinpoor Z. Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial. BMC Res Notes. 2024 Jan 25;17(1):38. [PMC free article: PMC10809558] [PubMed: 38273327]
97. Lumbiganon P, Laopaiboon M, Thinkhamrop J. Screening and treating asymptomatic bacteriuria in pregnancy. Curr Opin Obstet Gynecol. 2010 Apr;22(2):95-9. [PubMed: 20139763]
98. Haas CR, Li G, Hyams ES, Shah O. Delayed Decompression of Obstructing Stones with Urinary Tract Infection is Associated with Increased Odds of Death. J Urol. 2020 Dec;204(6):1256-1262. [PubMed: 32501124]
99. Vouloumanou EK, Rafailidis PI, Kazantzi MS, Athanasiou S, Falagas ME. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Curr Med Res Opin. 2008 Dec;24(12):3423-34. [PubMed: 19032124]
100. Squadrito FJ, del Portal D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 29, 2023. Nitrofurantoin. [PubMed: 29262089]
101. Padberg S, Wacker E, Meister R, Panse M, Weber-Schoendorfer C, Oppermann M, Schaefer C. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. Antimicrob Agents Chemother. 2014 Aug;58(8):4392-8. [PMC free article: PMC4136025] [PubMed: 24841264]
102. Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018 Aug;125(9):1069-1076. [PubMed: 29319210]
103. Jolley JA, Wing DA. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes. Drugs. 2010 Sep 10;70(13):1643-55. [PubMed: 20731473]
104. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, Panagaki A, Melachroinopoulos N, Drakou E, Marousis K, Chrysos G, Spyrou A, Alexiou N, Symbardi S, Alexiou Z, Lagou S, Kolonia V, Gkavogianni T, Kyprianou M, Anagnostopoulos I, Poulakou G, Lada M, Makina A, Roulia E, Koupetori M, Apostolopoulos V, Petrou D, Nitsotolis T, Antoniadou A, Giamarellos-Bourboulis EJ. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med. 2021 Jan 15;203(2):202-210. [PMC free article: PMC7874409] [PubMed: 32757963]
105. Ribeiro VST, Bail L, Ito CAS, Andrade AP, Arend LNVS, Suss PH, Nogueira KDS, Walflor HSM, Faoro H, Kuczera LCSM, Vicenzi FJ, Tuon FF. In vitro susceptibility to fosfomycin in clinical and environmental extended-spectrum beta-lactamase producing and/or ciprofloxacin-non-susceptible Escherichia coli isolates. Rev Inst Med Trop Sao Paulo. 2024;66:e5. [PMC free article: PMC10846478] [PubMed: 38324871]
106. Bilal M, El Tabei L, Büsker S, Krauss C, Fuhr U, Taubert M. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. [PMC free article: PMC8613110] [PubMed: 34420182]
107. Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020 Jul 01;75(7):1993-1997. [PubMed: 32303061]
108. Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Giner-Oncina L, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Alvarez RM, Dueñas CJ, Calvo-Montes J, Silva JT, Cárdenes MA, Lecuona M, Pomar V, Valiente de Santis L, Yagüe-Guirao G, Lobo-Acosta MA, Merino-Bohórquez V, Pascual A, Rodríguez-Baño J., REIPI-GEIRAS-FOREST group. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 04;5(1):e2137277. [PMC free article: PMC8759008] [PubMed: 35024838]
109. Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, Das AF, Skarinsky D, Eckburg PB, Ellis-Grosse EJ. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019 Nov 27;69(12):2045-2056. [PMC free article: PMC6880332] [PubMed: 30861061]
110. Pipitone G, Di Bella S, Maraolo AE, Granata G, Gatti M, Principe L, Russo A, Gizzi A, Pallone R, Cascio A, Iaria C. Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics (Basel). 2023 Nov 23;12(12) [PMC free article: PMC10741068] [PubMed: 38136687]
111. Burgos RM, Rodvold KA. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections. Future Microbiol. 2019 Apr;14:461-475. [PubMed: 30854892]
112. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. Open Forum Infect Dis. 2022 Jan;9(1):ofab620. [PMC free article: PMC8754378] [PubMed: 35036466]
113. Sojo-Dorado J, López-Hernández I, Hernández-Torres A, Retamar-Gentil P, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Álvarez RM, Dueñas CJ, Calvo-Montes J, Lecuona M, Pomar V, Borreguero I, Palomo-Jiménez V, Docobo-Pérez F, Pascual Á, Rodríguez-Baño J. Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial. J Antimicrob Chemother. 2023 Jul 05;78(7):1658-1666. [PMC free article: PMC10775153] [PubMed: 37260299]
114. Souza RB, Trevisol DJ, Schuelter-Trevisol F. Bacterial sensitivity to fosfomycin in pregnant women with urinary infection. Braz J Infect Dis. 2015 May-Jun;19(3):319-23. [PMC free article: PMC9425403] [PubMed: 25626961]
115. Chaves BJ, Tadi P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 10, 2023. Gentamicin. [PubMed: 32491482]
116. Sizar O, Rahman S, Sundareshan V. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Amikacin. [PubMed: 28613658]
117. Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020 Aug 01;75(8):2307-2313. [PubMed: 32451549]
118. Zohar I, Schwartz O, Yossepowitch O, David SSB, Maor Y. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020 Feb 01;75(2):458-465. [PubMed: 31691817]
119. Frimodt-Møller N, Bjerrum L. Treating urinary tract infections in the era of antibiotic resistance. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1301-1308. [PubMed: 37922147]
120. Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist. 2012 Apr;18(2):189-92. [PubMed: 22204597]
121. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother. 2000 Sep;46 Suppl 1:35-9; discussion 63-5. [PubMed: 11051622]
122. Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E, Therapy OBOSG’ROTPESFI. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics (Basel). 2022 May 31;11(6) [PMC free article: PMC9220249] [PubMed: 35740157]
123. Hansen BÅ, Grude N, Lindbæk M, Stenstad T. The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study. BMC Infect Dis. 2022 May 19;22(1):478. [PMC free article: PMC9118732] [PubMed: 35590284]
124. Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [PubMed: 14527775]
125. Bethel J. Acute pyelonephritis: risk factors, diagnosis and treatment. Nurs Stand. 2012 Oct 3-9;27(5):51-6; quiz 58. [PubMed: 23256302]
126. Husain S, Alroumoh M, Mohan P, El-Kass G, Seshan SV, Galler M. Acute kidney injury from pyelonephritis in an elderly man: case report. Int Urol Nephrol. 2011 Sep;43(3):925-8. [PubMed: 21739178]
127. De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics (Basel). 2021 Apr 01;10(4) [PMC free article: PMC8066587] [PubMed: 33915821]
128. Chung VY, Tai CK, Fan CW, Tang CN. Severe acute pyelonephritis: a review of clinical outcome and risk factors for mortality. Hong Kong Med J. 2014 Aug;20(4):285-9. [PubMed: 24625386]
129. Shields J, Maxwell AP. Acute pyelonephritis can have serious complications. Practitioner. 2010 Apr;254(1728):19, 21, 23-4, 2. [PubMed: 20486480]
130. Stone SC, Mallon WK, Childs JM, Docherty SD. Emphysematous pyelonephritis: clues to rapid diagnosis in the Emergency Department. J Emerg Med. 2005 Apr;28(3):315-319. [PubMed: 15769576]
131. Aggarwal N, Leslie SW, Lotfollahzadeh S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 2, 2024. Recurrent Urinary Tract Infections. [PubMed: 32491411]
132. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001 Mar 01;183 Suppl 1:S1-4. [PubMed: 11171002]
133. Saul H, Deeney B, Cassidy S, Kwint J, Harding C. Methenamine is as effective as antibiotics at preventing urinary tract infections. BMJ. 2023 Jan 17;380:72. [PubMed: 36649970]
134. Harding C, Chadwick T, Homer T, Lecouturier J, Mossop H, Carnell S, King W, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess. 2022 May;26(23):1-172. [PubMed: 35535708]
135. Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022 Mar 09;376:e068229. [PMC free article: PMC8905684] [PubMed: 35264408]
136. Harris E. Updated Meta-analysis: Cranberry Products Reduced UTI Risk. JAMA. 2023 May 23;329(20):1730. [PubMed: 37133890]
137. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD001321. [PMC free article: PMC7027998] [PubMed: 23076891]
138. Caretto M, Giannini A, Russo E, Simoncini T. Preventing urinary tract infections after menopause without antibiotics. Maturitas. 2017 May;99:43-46. [PubMed: 28364867]
139. Lenger SM, Chu CM, Ghetti C, Durkin MJ, Jennings Z, Wan F, Sutcliffe S, Lowder JL. d-Mannose for Recurrent Urinary Tract Infection Prevention in Postmenopausal Women Using Vaginal Estrogen: A Randomized Controlled Trial. Urogynecology (Phila). 2023 Mar 01;29(3):367-377. [PubMed: 36808931]
140. Salvatore S, Ruffolo AF, Stabile G, Casiraghi A, Zito G, De Seta F. A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections. Eur Urol Focus. 2023 Jul;9(4):654-659. [PubMed: 36621376]

Disclosure: Mariya Belyayeva declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Disclosure: Jordan Jeong declares no relevant financial relationships with ineligible companies.